Regencell Bioscience (NASDAQ:RGC) Trading 30% Higher – Here’s What Happened

Regencell Bioscience Holdings Limited (NASDAQ:RGC) traded up 30% during trading on Thursday . The company traded as high as $31.00 and last traded at $28.49. 661,503 shares changed hands during mid-day trading, a decline of 41% from the average session volume of 1,120,724 shares. The stock had previously closed at $21.91.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Regencell Bioscience in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Regencell Bioscience Stock Performance

The stock has a 50-day moving average of $21.17 and a 200-day moving average of $17.10.

Institutional Investors Weigh In On Regencell Bioscience

A number of large investors have recently bought and sold shares of RGC. XTX Topco Ltd acquired a new position in shares of Regencell Bioscience in the 3rd quarter valued at approximately $598,000. Squarepoint Ops LLC bought a new position in Regencell Bioscience in the second quarter valued at approximately $1,701,000. BNP Paribas Financial Markets acquired a new position in Regencell Bioscience during the second quarter valued at approximately $768,000. Geode Capital Management LLC lifted its stake in Regencell Bioscience by 5,637.5% during the second quarter. Geode Capital Management LLC now owns 391,066 shares of the company’s stock worth $6,664,000 after purchasing an additional 384,250 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Regencell Bioscience in the 2nd quarter valued at $222,000. 0.13% of the stock is currently owned by institutional investors and hedge funds.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.